Details of the Drug Combinations

General Information of This Drug (ID: DMCVBQD)

Drug Name

MLN1117 DMCVBQD

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
MLN1117 + LY335979	DCF02YB	LY335979	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
MLN1117 + Elacridar	DC6V48B	Elacridar	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
------------------------------------------------------------------------------------

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
MLN1117 + Canagliflozin	DCNNTP4	Canagliflozin	Breast Cancer	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02393209) Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT04073680) A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors